209 related articles for article (PubMed ID: 29363975)
1. Pulmonary Delivery of Ceftazidime for the Treatment of Melioidosis in a Murine Model.
Ruiz SI; Bowen LE; Bailey MM; Berkland C
Mol Pharm; 2018 Mar; 15(3):1371-1376. PubMed ID: 29363975
[TBL] [Abstract][Full Text] [Related]
2. Formulation and Characterization of Nanocluster Ceftazidime for the Treatment of Acute Pulmonary Melioidosis.
Ruiz SI; El-Gendy N; Bowen LE; Berkland C; Bailey MM
J Pharm Sci; 2016 Nov; 105(11):3399-3408. PubMed ID: 27639659
[TBL] [Abstract][Full Text] [Related]
3. Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
Feterl M; Govan B; Engler C; Norton R; Ketheesan N
Int J Antimicrob Agents; 2006 Nov; 28(5):460-4. PubMed ID: 17046208
[TBL] [Abstract][Full Text] [Related]
4. Use of a low-dose steroid as an adjunct in the treatment, in mice, of severe sepsis caused by Burkholderia pseudomallei.
Panomket P; Chetchotisakd P; Sermswan RW; Pannengpetch P; Wongratanacheewin S
Ann Trop Med Parasitol; 2009 Oct; 103(7):635-46. PubMed ID: 19825285
[TBL] [Abstract][Full Text] [Related]
5. Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model.
Ulett GC; Norton RE; Hirst RG
Pathology; 1999 Aug; 31(3):264-7. PubMed ID: 10503275
[TBL] [Abstract][Full Text] [Related]
6. G-CSF immunotherapy for treatment of acute disseminated murine melioidosis.
Powell K; Ulett G; Hirst R; Norton R
FEMS Microbiol Lett; 2003 Jul; 224(2):315-8. PubMed ID: 12892898
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
Propst KL; Troyer RM; Kellihan LM; Schweizer HP; Dow SW
Antimicrob Agents Chemother; 2010 May; 54(5):1785-92. PubMed ID: 20176901
[TBL] [Abstract][Full Text] [Related]
8. Endophthalmitis: potential benefits of repeated intravitreal injections of antibiotics.
Hui M; Lam WH; Ho WH; Chan CY
J Clin Microbiol; 2008 Apr; 46(4):1573. PubMed ID: 18387965
[No Abstract] [Full Text] [Related]
9. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis.
Soontornpas C; Saraya S; Chulasiri M; Chindavijak B; Mootsikapun P
Int J Antimicrob Agents; 2005 Nov; 26(5):403-7. PubMed ID: 16216470
[TBL] [Abstract][Full Text] [Related]
10. Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response.
Cummings JE; Slayden RA
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005209. PubMed ID: 28081127
[TBL] [Abstract][Full Text] [Related]
11. Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis.
Cummings JE; Lunde CS; Alley MRK; Slayden RA
PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011795. PubMed ID: 38011278
[TBL] [Abstract][Full Text] [Related]
12. Characterization of pathogenesis of and immune response to Burkholderia pseudomallei K96243 using both inhalational and intraperitoneal infection models in BALB/c and C57BL/6 mice.
Bearss JJ; Hunter M; Dankmeyer JL; Fritts KA; Klimko CP; Weaver CH; Shoe JL; Quirk AV; Toothman RG; Webster WM; Fetterer DP; Bozue JA; Worsham PL; Welkos SL; Amemiya K; Cote CK
PLoS One; 2017; 12(2):e0172627. PubMed ID: 28235018
[TBL] [Abstract][Full Text] [Related]
13. Why is the response rate slow in ceftazidime therapy for melioidosis?
Puthucheary SD; Sam IC
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):5-7. PubMed ID: 22149608
[No Abstract] [Full Text] [Related]
14. Farnesol increases the susceptibility of Burkholderia pseudomallei biofilm to antimicrobials used to treat melioidosis.
Castelo-Branco DS; Riello GB; Vasconcelos DC; Guedes GM; Serpa R; Bandeira TJ; Monteiro AJ; Cordeiro RA; Rocha MF; Sidrim JJ; Brilhante RS
J Appl Microbiol; 2016 Mar; 120(3):600-6. PubMed ID: 26669506
[TBL] [Abstract][Full Text] [Related]
15. Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis.
Häussler S; Rohde M; Steinmetz I
Med Microbiol Immunol; 1999 Nov; 188(2):91-7. PubMed ID: 10753061
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ceftazidime in a murine model following a lethal aerosol exposure to Burkholderia pseudomallei.
Pfefferle DA; Hackett M; Anderson MS; Gibbs S; Henning LN; Joice AC; Meister GT
Sci Rep; 2023 Mar; 13(1):4047. PubMed ID: 36899021
[TBL] [Abstract][Full Text] [Related]
17. Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei.
Wilson WJ; Afzali MF; Cummings JE; Legare ME; Tjalkens RB; Allen CP; Slayden RA; Hanneman WH
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005065. PubMed ID: 27792775
[TBL] [Abstract][Full Text] [Related]
18. Glyburide reduces bacterial dissemination in a mouse model of melioidosis.
Koh GC; Weehuizen TA; Breitbach K; Krause K; de Jong HK; Kager LM; Hoogendijk AJ; Bast A; Peacock SJ; van der Poll T; Steinmetz I; Wiersinga WJ
PLoS Negl Trop Dis; 2013; 7(10):e2500. PubMed ID: 24147174
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of post exposure administration of doxycycline in a murine model of inhalational melioidosis.
Gelhaus HC; Anderson MS; Fisher DA; Flavin MT; Xu ZQ; Sanford DC
Sci Rep; 2013; 3():1146. PubMed ID: 23359492
[TBL] [Abstract][Full Text] [Related]
20. An in situ high-throughput screen identifies inhibitors of intracellular
Bulterys PL; Toesca IJ; Norris MH; Maloy JP; Fitz-Gibbon ST; France B; Toffig B; Morselli M; Somprasong N; Pellegrini M; Schweizer HP; Tuanyok A; Damoiseaux R; French CT; Miller JF
Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18597-18606. PubMed ID: 31439817
[No Abstract] [Full Text] [Related]
[Next] [New Search]
